Artra Group Corporation (6029) AI Stock Analysis

• Market Cap: ¥1.56B
• Dividend Yield: N/A
• Average Volume (3M): 89.29K
• Price to Earnings (P/E): 6.0
• Beta (1Y): 0.81
• Revenue Growth: -10.34%
• EPS Growth: 259.78%
• Country: JP
• Employees: 142
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 7.73
• Shares Outstanding: 10,287,000
• 10 Day Avg. Volume: 88,380
• 30 Day Avg. Volume: 89,290
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 0.44
• P/FCF Ratio: 7.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ¥167.00 ▼(-1.76% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily supported by improving financial health (profitability recovery and deleveraging) and a low P/E valuation, but is held back by weak technicals (below major moving averages with negative momentum) and the fundamental risk of multi-year revenue contraction and earnings/cash-flow volatility.

Positive Factors

Improving profit margins

The company restored positive and healthier margins in 2025 (net ~6.6%, EBITDA ~6.3%, gross ~34%), reflecting better pricing, cost control and product mix. Stronger margins enhance earnings resilience versus sales weakness and sustain internal funding for operations and investment.

Deleveraging and stronger balance sheet

Leverage falling to ~0.62x after earlier elevated levels reduces interest burden and default risk, increasing financial flexibility. Lower leverage supports consistent capex, R&D and the ability to absorb cyclical shocks over the medium term, improving strategic optionality.

Positive and improving cash generation

Return to positive operating and free cash flow with FCF covering a large share of net income strengthens internal funding for growth and deleveraging. Sustained cash generation underpins capital allocation and reduces dependence on external financing if the trend continues.

Negative Factors

Multi-year revenue contraction

Persistent top-line decline erodes scale advantages, limits pricing power and reduces ability to leverage fixed costs. Continued revenue shrinkage can offset margin gains, constrain reinvestment in products and weigh on long-term growth prospects if not reversed.

Earnings and cash-flow volatility

Intermittent net losses and historically uneven operating cash flow complicate forecasting and capital planning. Volatility increases risk of covenant breaches, forces conservative balance-sheet policies, and undermines confidence in recently improved profitability unless consistency is proven.

Exposure to cyclical end markets

Concentration in construction, electronics and automotive ties revenue to cyclical industrial demand. Downturns in these sectors can quickly reverse margin and cash-flow improvements, amplifying the company's revenue and earnings sensitivity to macroeconomic cycles.

Artra Group Corporation Business Overview & Revenue Model

Company Description

Artra Group Corporation provides support services for acupuncture and osteopathic hospitals in Japan. The company offers billing services; and HONEY-STYLE, a system, which specializes in word-of-mouth/reservation system for acupuncture and moxibustion hospital. It also operates Atlas Store, an EC site that sells consumables for acupuncture and moxibustion hospital; and a portal site providing information for judo reduction teachers, acupuncturists/kyu teachers, and anma massage shiatsu teachers through its website and e-mail magazine, as well as offers nursing care services. The company was formerly known as artra corporation and changed its name to Artra Group Corporation in 2021. Artra Group Corporation was founded in 2005 and is headquartered in Osaka, Japan.

How the Company Makes Money

Artra Group Corporation generates revenue through multiple key streams. The primary source of income comes from the sale of its advanced materials and coatings to various industries, including construction and electronics. Additionally, the company provides specialized consulting and technical services that support the implementation of its products, thereby creating an additional revenue stream. Strategic partnerships with industry leaders enhance Artra's market reach and product development capabilities, contributing significantly to its earnings. The company's focus on innovation and sustainability also allows it to capitalize on emerging market trends, thus driving future growth and profitability.

Artra Group Corporation Financial Statement Overview

Summary

Margins and profitability improved in 2025 (net margin ~6.6%, EBITDA margin ~6.3%) alongside healthier gross margin (~34%) and better leverage (debt-to-equity ~0.62x). Offsetting these gains, revenue has contracted for multiple years and results have been volatile (including a 2024 net loss and historically uneven cash flow).

Income Statement

Profitability has improved meaningfully versus earlier losses (2020–2021) and the company returned to solid profitability in 2025, with net margin at ~6.6% and EBITDA margin ~6.3%. Gross margin has also strengthened versus 2020 and remains healthy (~34% in 2025). Offsetting this, revenue has been shrinking for several years (down ~3.4% in 2025 after declines in 2023–2024), and earnings have been volatile (net loss in 2024). Overall: better margins and recovery, but weak top-line trajectory and inconsistent bottom-line performance.

Balance Sheet

Leverage is trending in the right direction: debt-to-equity improved from elevated levels in 2021–2023 (above 1.0x) to ~0.62x in 2025, reflecting deleveraging and a stronger equity base. Total assets have been relatively stable, suggesting no major balance sheet contraction. The key watch-out is that leverage was high not long ago and profitability volatility (including the 2024 loss) can pressure equity returns in weaker years.

Cash Flow

Cash generation has improved: operating cash flow and free cash flow are positive in 2024–2025, with 2025 free cash flow covering most of reported earnings (free cash flow is ~86% of net income). However, cash flow has been uneven historically (negative operating/free cash flow in 2021–2022), and free cash flow declined in 2024. Overall: currently supportive of earnings, but the multi-year consistency is not yet fully proven.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.07B	3.93B	4.23B	4.50B	4.67B	3.16B
Gross Profit	1.35B	1.35B	1.33B	1.46B	1.57B	876.25M
EBITDA	318.30M	246.22M	146.84M	228.12M	190.55M	-163.55M
Net Income	142.57M	258.29M	-36.74M	53.00M	2.10M	-351.12M
Balance Sheet
Total Assets	3.81B	4.13B	4.11B	4.57B	4.65B	5.60B
Cash, Cash Equivalents and Short-Term Investments	1.02B	1.13B	1.05B	1.14B	1.23B	1.84B
Total Debt	1.18B	1.05B	1.28B	1.53B	1.91B	2.43B
Total Liabilities	2.26B	2.43B	2.68B	3.13B	3.35B	4.16B
Stockholders Equity	1.55B	1.70B	1.44B	1.45B	1.31B	1.44B
Cash Flow
Free Cash Flow	0.00	246.64M	122.36M	142.00M	-288.93M	-264.76M
Operating Cash Flow	0.00	287.21M	200.85M	217.00M	-132.55M	-208.56M
Investing Cash Flow	0.00	24.68M	-31.16M	-11.00M	-154.17M	-563.84M
Financing Cash Flow	0.00	-233.24M	-259.74M	-300.00M	-314.62M	895.50M

Artra Group Corporation Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 170.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6029, the sentiment is Negative. The current price of 170 is above the 20-day moving average (MA) of 160.60, below the 50-day MA of 171.10, and below the 200-day MA of 179.13, indicating a bearish trend. The MACD of -5.37 indicates Positive momentum. The RSI at 32.61 is Neutral, neither overbought nor oversold. The STOCH value of 27.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6029.

Artra Group Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9220	81 Outperform	¥2.98B	6.24	―	2.82%	4.82%	9.78%
2425	75 Outperform	¥3.02B	13.13	―	2.56%	-3.06%	-38.56%
9214	69 Neutral	¥2.01B	15.20	―	―	32.45%	58.25%
2373	60 Neutral	¥5.79B	15.40	―	4.07%	6.08%	38.00%
6029	57 Neutral	¥1.56B	6.04	―	―	-10.34%	259.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7362	49 Neutral	¥1.22B	14.77	―	―	2.81%	-42.50%